M. O’Connor

CTRIAL-IE (ICORG) 15–34: The impact of the 21 gene breast recurrence score® assay on chemotherapy prescribing in oestrogen receptor positive, lymph node positive early stage breast cancer in Ireland

William J. Mullally, A Hassan, N.M. Keegan, Connor Gerard O’Leary et autres

BACKGROUND: The 21-gene Breast Recurrence Score® (Oncotype DX®) assay has improved the selection of patients for chemotherapy in early breast cancer. Internationally, this test is used in lymph node positive disease, but at the time this study was conducted, it was not …

ie (code pays fourni par la source)

ESMO Resilience Task Force recommendations to manage psychosocial risks, optimise well-being, and reduce burnout in oncology

Kok Haw Jonathan Lim, Konstantinos Kamposioras, Elena Élez, John B.A.G. Haanen et autres

BACKGROUND: Burnout in health care professionals (HCPs) results from exposure to psychosocial risks at work. Left unaddressed, burnout can lead to chronic health problems, increased staff turnover, reduced work hours, absenteeism, and early retirement from clinical practice, thus impacting patient care. The …

gb, es, nl, au, ie, de, be, fr (code pays fourni par la source)

1539MO Oncologists’ voices in time of crisis: Findings from the ESMO Resilience Task Force survey series on how members can be helped and supported – A qualitative analysis

Claire Hardy, Eleanor Thorne, M. O’Connor, M.E. Elez Fernandez et autres

gb, ie, es, be, au, nl (code pays fourni par la source)

Qualitative exploration of patients’ experiences with Intrabeam targeted intraoperative radiotherapy (TARGIT-IORT) and External-Beam Radiotherapy Treatment (EBRT)

Sandeep Kumar Bagga, Natalie Swiderska, Charlotte Hooker, Jenny Royle et autres

Abstract For patients with early breast cancer undergoing breast conserving surgery, radiotherapy is given either as a post-operative course of External-Beam RadioTherapy (EBRT), given daily for over a number of days and often weeks, or with TARGeted Intrabeam Intraoperative radioTherapy (TARGIT-IORT), which …

us, gb (code pays fourni par la source)

249P A retrospective review of patients receiving trastuzumab deruxtecan across five centres in Ireland with a subgroup analysis of patients with CNS involvement assessing response in the CNS

Conleth Murphy, Karine E. Ronan, J. Buchalter, Ruth H. Keogh et autres

Approximately 30%-%0% of patients with HER2-positive breast cancer will develop central nervous system (CNS) metastasis. Trastuzumab deruxtecan (T-DXd) is known to have clinically relevant activity in HER2- positive metastatic breast cancer (MBC) patients who have progressed on prevsious lines of treatment. DESTINY-Breast01 …

ie (code pays fourni par la source)

The impact of COVID-19 on oncology professionals—one year on: lessons learned from the ESMO Resilience Task Force survey series

Kok Haw Jonathan Lim, Krithika Murali, Eleanor Thorne, Kevin Punie et autres

BACKGROUND: COVID-19 has had a significant impact on the well-being and job performance of oncology professionals globally. The European Society for Medical Oncology (ESMO) Resilience Task Force collaboration set out to investigate and monitor well-being since COVID-19 in relation to work, lifestyle …

gb, au, be, de, ie, es, us, it, in, se, nl (code pays fourni par la source)

Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER)

Joan Albanell, María Teresa Martínez, Manuel R. Ramos, M. O’Connor et autres

BACKGROUND: The potential benefit of adding palbociclib to fulvestrant as first-line treatment in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative endocrine-sensitive advanced breast cancer (ABC) patients remains uncharacterized. PATIENTS AND METHODS: In this randomized (1:1), double-blind, phase II study, …

es, ie (code pays fourni par la source)

1851P Introduction of a G8 screening programme for older cancer patients

M. Hannan, Mairead Marion Hennessy, Declan Walsh, S. Scally et autres

ie (code pays fourni par la source)

1561O The future of the oncology workforce since COVID-19: Results of the ESMO Resilience Task Force survey series

Kok Haw Jonathan Lim, Kevin Punie, Christoph Oing, Eleanor Thorne et autres

gb, be, de, au, ie, es, pt, it, in, se, nl (code pays fourni par la source)

The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II

Kok Haw Jonathan Lim, Krithika Murali, K. Kamposioras, Kevin Punie et autres

BACKGROUND: The COVID-19 pandemic has resulted in significant changes to professional and personal lives of oncology professionals globally. The European Society for Medical Oncology (ESMO) Resilience Task Force collaboration aimed to provide contemporaneous reports on the impact of COVID-19 on the lived …

gb, au, be, de, ie, pt, es, it, in, se, nl (code pays fourni par la source)

The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration

Susana N. Banerjee, Kok Haw Jonathan Lim, Krithika Murali, Konstantinos Kamposioras et autres

BACKGROUND: The impact of the coronavirus disease 2019 (COVID-19) pandemic on well-being has the potential for serious negative consequences on work, home life, and patient care. The European Society for Medical Oncology (ESMO) Resilience Task Force collaboration set out to investigate well-being …

gb, au, be, de, ie, in, it, es, pt, se, nl (code pays fourni par la source)

LBA70_PR The impact of COVID-19 on oncology professionals: Initial results of the ESMO resilience task force survey collaboration

Susana N. Banerjee, Kok Haw Jonathan Lim, K. Kamposioras, Krithika Murali et autres

gb, au, de, ie, in, it, es, se (code pays fourni par la source)